"BRCA2 Protein" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A large, nuclear protein, encoded by the BRCA2 gene (GENE, BRCA2). Mutations in this gene predispose humans to breast and ovarian cancer. The BRCA2 protein is an essential component of DNA repair pathways, suppressing the formation of gross chromosomal rearrangements. (from Genes Dev. 2000;14(11):1400-6)
| Descriptor ID |
D024682
|
| MeSH Number(s) |
D12.776.313.249 D12.776.624.776.101 D12.776.660.105
|
| Concept/Terms |
BRCA2 Protein- BRCA2 Protein
- FANCD1 Protein
- Fanconi Anemia Complementation Group D1 Protein
- Fanconi Anemia Group D1 Protein
- BRCA2 Gene Product
- Breast Cancer 2 Gene Product
- Fanconi Anemia Group D1 Complementing Protein
- Breast Cancer 2 Protein
|
Below are MeSH descriptors whose meaning is more general than "BRCA2 Protein".
Below are MeSH descriptors whose meaning is more specific than "BRCA2 Protein".
This graph shows the total number of publications written about "BRCA2 Protein" by people in this website by year, and whether "BRCA2 Protein" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 6 | 6 |
| 2001 | 0 | 2 | 2 |
| 2002 | 1 | 0 | 1 |
| 2004 | 1 | 1 | 2 |
| 2005 | 0 | 2 | 2 |
| 2007 | 2 | 1 | 3 |
| 2008 | 1 | 1 | 2 |
| 2009 | 3 | 0 | 3 |
| 2010 | 2 | 0 | 2 |
| 2011 | 4 | 0 | 4 |
| 2012 | 2 | 0 | 2 |
| 2013 | 0 | 1 | 1 |
| 2014 | 3 | 1 | 4 |
| 2015 | 3 | 0 | 3 |
| 2016 | 3 | 0 | 3 |
| 2017 | 3 | 2 | 5 |
| 2018 | 6 | 2 | 8 |
| 2019 | 9 | 7 | 16 |
| 2020 | 5 | 5 | 10 |
| 2021 | 9 | 3 | 12 |
| 2022 | 2 | 3 | 5 |
| 2023 | 0 | 8 | 8 |
| 2024 | 1 | 4 | 5 |
| 2025 | 2 | 3 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "BRCA2 Protein" by people in Profiles.
-
Pathogenic Variants, Family History, and Cumulative Risk of Breast Cancer in US Women. JAMA Oncol. 2025 Dec 01; 11(12):1458-1469.
-
Estimating Cancer Penetrance in Carriers of BRCA2 Pathogenic Variants Using Cancer-Specific Polygenic Scores. Cancer Med. 2025 Jun; 14(11):e70990.
-
Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification. Nat Commun. 2025 May 25; 16(1):4852.
-
Breast Cancer Risk Modification in Women with Pathogenic Variants in BRCA1, BRCA2, ATM, CHEK2, and PALB2. Cancer Res Commun. 2025 May 01; 5(5):783-791.
-
Association of gene variant type and location with breast cancer risk in the general population. Ann Oncol. 2025 Aug; 36(8):954-963.
-
Aggressive renal cell carcinoma with somatic BRCA2 mutation-an emerging entity? A case report with literature review. Virchows Arch. 2025 Aug; 487(2):471-476.
-
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway). Clin Cancer Res. 2024 Oct 01; 30(19):4318-4328.
-
Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jun; 8:e2400026.
-
Functional analysis and clinical classification of 462 germline BRCA2 missense variants affecting the DNA binding domain. Am J Hum Genet. 2024 03 07; 111(3):584-593.
-
Germline loss-of-function BRCA1 and BRCA2 mutations and risk of de novo hematopoietic malignancies. Haematologica. 2024 01 01; 109(1):351-356.